As of today, you'll begin to notice
a new look on many of your favorite PHA website pages.
As we continue to make the site
more user-friendly and content rich, we welcome your input: web@phassociation.org
We're especially looking for people
willing to help us develop meaningful content specific to our
various constituent groups: patients, medical professionals, caregivers
and the media.
Debbie Storey, whose 15-year-old daughter
Natasha urgently needs a heart and lung transplant, has joined calls for
Britain to adopt a system of presumed consent, allowing doctors to use
organs unless asked not to.
At present, doctors must get permission
before an organ can be used for transplant surgery. And even if someone
carries an organ donor card, relatives can veto their loved one's request
and stop a transplant going ahead.
United Therapeutics Announces Approval
of Remodulin(R) in France
TRIANGLE--FirstCall/ -- United Therapeutics Corporation (NASDAQ:UTHR)
announced today that AFSSAPS, the French drug regulatory agency, has issued
an approval letter for Remodulin (treprostinil sodium) Injection for subcutaneous
treatment of NYHA Class III Primary Pulmonary Hypertension patients. The
approval letter did not request any additional clinical trials of subcutaneous
Remodulin. AFSSAPS has indicated that the mutual recognition approval
process with other countries in the European Union will be initiated in
May 2005.
Pulmonary
Hypertension - A Patient's Survival Guide The premiere information resource
for people dealing with PH -- they have ARRIVED and are ready to
ship!!!
The author, a PH patient herself,
knows what it is like to live with the disease. She talked to many
other patients, doctors, and researchers while writing the Survival
Guide. Dr. Ronald J. Oudiz and a team of physicians with a deep
knowledge of PH edited the book for accuracy.
New edition contains a chart
of 15 drugs used to treat PH; results of recent
clinical trials;
in-depth discussion of PH secondary to other diseases
or conditions;
a new chapter on what to eat if you have PH; and much, much more!
CoTherix Reports Positive Clinical Data
From STEP Study
SOUTH SAN FRANCISCO, Calif., March 08,
2005 /PRNewswire-FirstCall/ -- CoTherix, Inc. announced today top-line
safety and efficacy results from the STEP clinical study. The analysis
of this study showed that the combination of Ventavis(R) (iloprost) Inhalation
Solution added to Tracleer(R) (bosentan) therapy was well tolerated and
provided clinical benefit in patients with pulmonary arterial hypertension
(PAH).
After numerous inquiries about
monthly giving, PHA has created the Sustainers Circle. The Sustainers
Circle is a quick and easy way to provide PHA with steady reliable
income each month. Simply go to https://www.phassociation.org/help/donatenow.htm.
There you can specify the amount that you authorize PHA to charge
to your credit card each month.
Sign up once and that's all there
is to it! There is nothing additional for you to remember or do.
The monthly transactions are safe, secure and reliable. You can
increase, decrease or stop your participation at any time by contacting
PHA.
As a member of the Sustainers Circle
you will be helping to improve the lives of those affected by pulmonary
hypertension.
For more information about the
Sustainers Circle, contact PHA's Development Director Katherine
Lowe, CFRE at 301.565.3004 or email at katherine@phassociation.org.
Committee
for Orphan Medicinal Products March 2005 Meeting
Ambrisentan, from Uppsala
Medical Information System AB, for treatment of pulmonary arterial hypertension
and chronic thromboembolic pulmonary hypertension (review time: 54 days).
The
information provided on the PHA website is provided for general information
only. It is not intended as legal, medical or other professional
advice, and should not be relied upon as a substitute for consultations
with qualified professionals who are familiar with your individual
needs.
